Background Statin drugs are known to cause dose-dependent abnormalities in liver function tests (LFTs), with elevations three times the upper limits of normal of the aminotransferase enzymes in up to 2.5% of patients on the highest prescribable doses. The Program on the Surgical Control of the Hyperlipidemias (POSCH) trial employed no hypocholesterolaemic drugs and used a surgical procedure, partial ileal bypass, as the intervention modality.
Methods Serum total bilirubin, alkaline phosphatase and serum glutamic-oxaloacetic transaminase (SGOT) (equivalent to aspartate aminotransferase [AST]), were the LFTs obtained in POSCH at baseline, 3 months, annually for 5 years, and at 7 or 10 years postrandomization.
Results Abnormal values were found for total bilirubin in seven of 416 control group (CG) patients (1.68%) and in 34 of 373 intervention group (IG) patients (9.16%) (P=0.001); for alkaline phosphatase, in 28 of 378 (7.41%) and in 41 of 326 (12.58%) (P=0.0214); and for SGOT, in 102 of 412 (24.76%) and in 161 of 372 (43.28%) (P=0.001). Values twice the upper limit of normal occurred in 1 CG and 1 IG patient for total bilirubin and for alkaline phosphatase, and in 11 CG and 7 IG patients for SGOT (NS). Values three times the upper limit of normal did not occur in any patient for total bilirubin or alkaline phosphatase, and occurred in 3 CG and 5 IG patients for SGOT (NS).
Conclusions In POSCH, the IG demonstrated statistically significant mild increases for total bilirubin, alkaline phosphatase and SGOT levels, with no significant increases in values twice or greater the upper limits of normal.
BlackDMBakker-ArkemaRGNawrockiJW.An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med1998; 158:577–584.
2.
SteinEPlotkinDBaysHDavidsonMDujovneCKorenmanSEffects of Simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol2000; 86:406–411.
3.
DavidsonMMcKenneyJSteinESchrottHBakker-ArkemaRFayyadRComparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol1997; 79:1475–1481.
4.
NawrockiJWWeissSRDavidsonMHSprecherDLSchwartzSLLupienPJReduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Biol1995; 15:678–682.
5.
NakadABatailleLHamoirVSempouxCHorsmansY.Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet1999; 353:1763–1764.
BuchwaldHVarcoRLMattsJPLongJMFitchLLCampbellGSEffect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). New Engl J Med1990; 323:946–955.
8.
BuchwaldHCamposCTVarcoRLBoenJRWilliamsSEHansenBJEffective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: Five-year posttrial follow-up report from the POSCH. Arch Intern Med1998; 158:1253–1261.
9.
Scandinavian Simvastatin Survival Study Group.Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet1994; 344:1383–1389.
10.
MAAS Investigators.Effect of simvastatin on coronary atheroma: A multicentre antiatheroma study. Lancet1994; 344:633–638.
11.
WatersDHigginsonLGladstonePKimballBLe MayMBoccuzziSJEffects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial. Circulation1994; 89:959–968.
12.
FurbergCDAdamsHPJrApplegateWBByingtonRPEspelandMAHartwellTEffect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994; 90:1679–1687.
13.
JukemaJWBruschkeAVvan BovenAJReiberJHBalETZwindermanAHEffects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS). Circulation1995; 91:2528–2540.
14.
ShepherdJCobbeSMFordIIslesCGLorimerARMacFarlanePWPrevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med1995; 333:1301–1307.
15.
BuchwaldHMattsJPFitchLLCamposCTSanmarcoMEAmplatzKChanges in sequential coronary arteriograms and subsequent coronary events. JAMA1992; 268:1429–1433.
16.
BuchwaldHCamposCTBoenJRNguyenPAWilliamsSE and The POSCH Group. Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: Report from the Program on the Surgical Control of the Hyperlipidemias (POSCH). J Am Coll Cardiol1995; 26:351–357.
17.
BuchwaldHBoenJRNguyenPAWilliamsSEMattsJP.Plasma lipids and cardiovascular risk: A POSCH report. Atherosclerosis2001; 154:221–217.
18.
BuchwaldHMooreRBVarcoRL.Surgical treatment of hyperlipidemia. Circulation1974; 49(suppl I):137.
19.
MooreRBFrantzIDJrBuchwaldH.Changes in cholesterol pool size, turnover rate, and fecal bile acid and sterol excretion after partial ileal bypass in hypercholesterolemic patients. Surgery1969; 65:98–108.
20.
SchwartzMZVarcoRLBuchwaldH.Liver function and morphology following distal ileal excision in the rabbit. Surg Forum1971; 22:355–356.
21.
MarubbioATBuchwaldHSchwartzMZVarcoRL.Hepatic lesions of central peri-cellular fibrosis in morbid obesity and after jejunoileal bypass. Am J Clin Path1976; 66:684–691.
22.
MarubbioATRuckerRDJrSchneiderPDHorstmannJPVarcoRLBuchwaldH.The liver in morbid obesity and following bypass surgery for obesity. Surg Clin N Am1979; 59:1079–1093.
